Browsing Tag
Keytruda
44 posts
Merck’s KEYNOTE-B96 trial signals survival benefit in platinum-resistant ovarian cancer, but MRK stock dips
Merck's KEYNOTE-B96 trial shows survival benefit in ovarian cancer. See what it means for patients, pipeline, and MRK stock. Read full analysis now.
Immutep (ASX: IMM) closing in on critical readout — biotech traders discuss risk vs reward heading into 2026
Immutep Limited surpasses 170 patients in its global Phase III NSCLC trial, setting up a 2026 futility readout that could redefine its immunotherapy pipeline.
Can Merck’s new Keytruda injection delay biosimilar threats and change cancer care forever?
Find out how Merck’s newly FDA-approved Keytruda QLEX injectable version aims to improve cancer care with faster, more convenient treatment. Read on.
How Merck’s Keytruda became a global immunotherapy benchmark in cancer treatment
Explore Keytruda’s journey from early PD-1 research to global immunotherapy dominance, with clinical, regulatory, and innovation context shaping cancer care in 2025.
Can Merck’s strategy around Keytruda formulations delay the biggest patent cliff in pharma history?
Can Merck’s subcutaneous Keytruda strategy soften the 2028 patent cliff? Explore how the drugmaker is diversifying and preparing for the biggest loss of exclusivity in pharma.
Can Merck rebuild its cardiovascular empire post-Keytruda? A closer look at its next decade of drug growth
With Keytruda’s patent expiry nearing, Merck is betting on enlicitide and sotatercept to build a new cardiovascular empire. Can it succeed?
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
Merus N.V. stock soars on breakthrough cancer trial: What drove MRUS to the top gainers list?
Merus N.V. stock jumped 32% on breakthrough cancer trial data. Find out what’s driving MRUS and what could come next for this biotech leader.
Innovent begins IBI363 pivotal study in melanoma immunotherapy
Innovent Biologics, Inc. (HKEX: 01801), a global biopharmaceutical company specializing in innovative oncology therapies, has dosed the first…
Scientists investigate NPRL2 gene therapy for hard-to-treat lung cancer—What they found
A significant study published in eLife suggests that NPRL2 gene therapy could offer a new therapeutic approach for…